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ABSTRACT Whole-genome sequencing (WGS) of microbial pathogens from clin-
ical samples is a highly sensitive tool used to gain a deeper understanding of
the biology, epidemiology, and drug resistance mechanisms of many infections.
However, WGS of organisms which exhibit low densities in their hosts is chal-
lenging due to high levels of host genomic DNA (gDNA), which leads to very
low coverage of the microbial genome. WGS of Plasmodium vivax, the most
widely distributed form of malaria, is especially difficult because of low parasite
densities and the lack of an ex vivo culture system. Current techniques used to
enrich P. vivax DNA from clinical samples require significant resources or are not
consistently effective. Here, we demonstrate that selective whole-genome amplifica-
tion (SWGA) can enrich P. vivax gDNA from unprocessed human blood samples and
dried blood spots for high-quality WGS, allowing genetic characterization of isolates
that would otherwise have been prohibitively expensive or impossible to sequence.
We achieved an average genome coverage of 24, with up to 95% of the P. vivax
core genome covered by 5 reads. The single-nucleotide polymorphism (SNP) char-
acteristics and drug resistance mutations seen were consistent with those of other
P. vivax sequences from a similar region in Peru, demonstrating that SWGA produces
high-quality sequences for downstream analysis. SWGA is a robust tool that will en-
able efficient, cost-effective WGS of P. vivax isolates from clinical samples that can
be applied to other neglected microbial pathogens.
IMPORTANCE Malaria is a disease caused by Plasmodium parasites that caused 214
million symptomatic cases and 438,000 deaths in 2015. Plasmodium vivax is the
most widely distributed species, causing the majority of malaria infections outside
sub-Saharan Africa. Whole-genome sequencing (WGS) of Plasmodium parasites from
clinical samples has revealed important insights into the epidemiology and mecha-
nisms of drug resistance of malaria. However, WGS of P. vivax is challenging due to
low parasite levels in humans and the lack of a routine system to culture the para-
sites. Selective whole-genome amplification (SWGA) preferentially amplifies the ge-
nomes of pathogens from mixtures of target and host gDNA. Here, we demonstrate
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that SWGA is a simple, robust method that can be used to enrich P. vivax genomic
DNA (gDNA) from unprocessed human blood samples and dried blood spots for
cost-effective, high-quality WGS.
Malaria is a mosquito-borne infection caused by protozoan parasites of the Plas-modium genus. Of the six Plasmodium species known to infect humans (1–3),
P. vivax is the most widely distributed, causing approximately half of all clinical cases of
malaria outside Africa (4). Whole-genome sequencing (WGS) of Plasmodium parasites
from clinical samples has revealed important insights into the biology, epidemiology,
and mechanisms of drug resistance of malaria (5–12). For P. vivax, WGS of clinical
isolates has the potential to uncover mechanisms underlying some of the unique
aspects of this parasite’s biology, such as distinguishing between reinfection and
relapse due to activation of dormant liver parasites. However, WGS of P. vivax from
clinical samples is challenging, mainly due to low parasite densities in clinical samples
compared to those of Plasmodium falciparum and the lack of a robust ex vivo culture
system.
Multiple techniques have been developed to enrich Plasmodium genomic DNA
(gDNA) from clinical samples, including leukocyte depletion (13–15), hybrid selection
with RNA baits (16, 17), short-term ex vivo culture (18), adaptation to growth in
splenectomized monkeys (9, 19), and single-cell sequencing (20). The majority of these
techniques require significant labor and resources. While leukocyte depletion is the
most cost-effective, it requires sample processing within 6 h of sample collection, which
is not feasible at many field sites and is not always effective. Two recent studies that
performed WGS on over 400 clinical isolates of P. vivax (15, 17) employed hybrid
selection and leukocyte depletion to enrich P. vivax gDNA from clinical samples.
Pearson et al. used leukocyte depletion on 292 clinical samples and had to eliminate
144 (49%) of their samples from further population genetics analysis due to low quality,
which often occurs due to contaminating human DNA (15). Hupalo et al. used hybrid
selection to enrich their samples, with 31 out of 170 sequences (21%) removed from
further analysis due to low quality (17). Although more frequently successful, the hybrid
selection technique requires either expensive synthetic RNA baits or a large amount of
pure P. vivax DNA to create the RNA baits, which is difficult to obtain. In addition, hybrid
selection can introduce bias, since it is approximately half as efficient at capturing
regions with GC contents of 50% (16).
An alternative method is selective whole-genome amplification (SWGA). SWGA has
been used to enrich submicroscopic DNA levels of the ape Plasmodium parasites,
P. reichenowi and P. gaboni, from whole-blood samples (21, 22) and P. falciparum
genomes from dried blood spots (23) for WGS. SWGA preferentially amplifies the
genomes of pathogens from complex mixtures of target and host DNA (Fig. 1) (24).
SWGA does not require separation of target DNA from background DNA, making it an
attractive option for pathogens that cannot be amplified in culture. DNA amplification
is carried out by the highly processive, strand-displacing phi29 DNA polymerase and a
set of pathogen-specific primers that target short (6 to 12 nucleotide) motifs that are
common in the pathogen genome and uncommon in the host genome. The strand
displacement function of phi29 results in the amplification of genomic regions where
primers bind frequently, leading to the preferential amplification of genomes with
frequent primer-binding sites. Here, we show that SWGA efficiently enriches P. vivax
gDNA from unprocessed human blood samples and dried blood spots for cost-
effective, high-quality whole-genome sequencing.
RESULTS
Primer design and optimization using P. vivax-infected whole-blood samples.
To perform SWGA on P. vivax gDNA from unprocessed human blood samples, we
designed primers that specifically amplified this parasite’s DNA using a previously
published approach for P. falciparum (22). Briefly, we identified the most frequently
occurring motifs of 6 to 12 nucleotides in length in the P. vivax Salvador-1 (Sal-1)
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reference genome. We selected the top 10,000 primers of each length, yielding a total
of 70,000 primers for further analysis. We filtered these primers based on characteristics
such as melting temperature (18 to 32°C), ability to homodimerize (no greater than 3
consecutive matches), binding frequencies on the human genome and Sal-1 genome
(less frequent than once every 500,000 bp and more frequent than once every
50,000 bp, respectively), and infrequent binding of the human mitochondrial genome
(less than 4 binding sites). Next, we removed primers predicted to bind the Sal-1
subtelomeres. These filters resulted in a pool of 222 primers. We separated these
primers into 6 sets that were predicted not to form heterodimers and identified the top
set (pvset1) of 10 primers using a selection algorithm described previously (22). gDNA
from an unprocessed P. vivax-infected whole-blood sample (MRL2) was subjected to
SWGA with primer set pvset1 prior to shotgun sequencing (see Fig. S1 in the supple-
mental material). SWGA significantly increased the percentage of reads that mapped to
the P. vivax Sal-1 reference genome, from 0.7% to 73.5% (see Fig. S1A), and improved
the genome coverage obtained from ~80 million bp of sequencing from 1.5% to 58%
(see Fig. S1B).
We observed that the genome coverage obtained per base pair sequenced was
lower than that achieved with SWGA of P. falciparum gDNA using the same primer set
design methods (22). Visual inspection of the P. vivax genome coverage from samples
subjected to SWGA revealed that coverage gaps were typically in regions with com-
paratively higher GC content (Fig. 2A). The P. falciparum genome is extremely AT rich,
with only 19.4% of bases consisting of G’s or C’s, while the GC content for the P. vivax
genome is 42.3% (9). The P. vivax genome also has an isochore structure: internal
chromosomal areas have a high GC content and subtelomeres and centromeres have
lower GC contents (25). Since phi29 DNA polymerase pauses more frequently during
strand displacement and primer extension in regions with a high GC content of DNA
(26), we hypothesized that differences in base composition could explain the more
uneven amplification of the P. vivax genome compared to that of P. falciparum.
We thus designed primer sets specifically targeting regions of the P. vivax Sal-1
reference genome with high GC content and poor coverage using the swga program
(https://github.com/eclarke/swga; unpublished data), a program that identifies and
scores SWGA primer sets (see Fig. S2 in the supplemental material). Primers were
FIG 1 Selective whole-genome amplification (SWGA) of Plasmodium vivax genomic DNA (gDNA) from
human blood samples. (A) SWGA primers bind frequently to Plasmodium vivax gDNA and infrequently to
human gDNA. (B) When phi29 encounters double-stranded gDNA, it displaces the newly synthesized
strand, opening new primer binding sites on the synthesized gDNA, leading to selective amplification of
templates with frequent primer binding sites. (C) Post-SWGA, the percentage of P. vivax DNA has
increased relative to the percentage of host DNA.
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designed to bind regions of the P. vivax Sal-1 genome that had even AT/GC compo-
sition, were longer than 195,000 bp, and had low sequence coverage when amplified
with pvset1. We identified 1,939 primer sets (consisting of up to 15 primers) with
minimal human genome binding and maximal P. vivax genome binding and scored
them based on evenness of binding, as well as mean distance between primer binding
sites in the foreground and background genomes. The primer set with the best score,
pvset1920, was chosen for subsequent testing. SWGA of an unprocessed human blood
sample with pvset1920 yielded overall superior P. vivax genome coverage compared to
that of SWGA with pvset1 (Fig. 3). Visual inspection of these post-SWGA P. vivax
sequences revealed that pvset1920 achieved improved coverage particularly in regions
with high GC content (Fig. 2B), with troughs in coverage in genomic regions of lower
GC content, which include the centromeres and subtelomeres.
Having developed a method that worked well for SWGA of P. vivax gDNA from
whole blood, we tested whether the method could also be applied to gDNA extracted
from dried blood spot samples. Dried blood spots are a common method of storing
patient and parasite DNA that utilizes a smaller volume of blood and does not require
immediate cold storage. DNA extracted from dried blood spots can have variable
quality depending on the method of collection and storage (27). SWGA has been used
to enrich P. falciparum DNA from dried blood spots for WGS (23), with an average of
48.1%  3.5% of the genome covered at 5 for samples with an average parasite
density of 73,601 parasites/l  19,399 (1.5% parasitemia). Since P. vivax clinical
samples generally have lower parasite densities, we wondered if it would be feasible to
obtain significant genome coverage on P. vivax from dried blood spots with SWGA. We
extracted DNA from blood spots obtained from symptomatic patients in Peru and
performed SWGA with pvset1920, achieving 73% and 42% genome coverage at 1 on
initial testing for samples with a high (sample C, 56,790 parasites/l; 1.1%) and low
(sample L, 2,572 parasites/l; 0.05%) level of parasitemia, respectively (see Fig. S3 in the
supplemental material).
FIG 2 Plasmodium vivax chromosomal coverage following SWGA using primer set pvset1 (A) or pvset1920 (B). The base compositions of chromosomes 2 and
6 were visualized in Geneious (version 9.1) using the P. vivax Sal-1 reference genome; green and blue lines represent percentages of AT and GC content,
respectively, plotted for 25-bp windows across the chromosome (scale shown above the graph). Shown in blue and red below are the corresponding MiSeq
read coverage depths using primer sets pvset1 and pvset1920, respectively. Coverage plots were generated using IGVTools (version 2.3.40) and are shown on
a log scale with maximum read depth indicated in the upper left corner of the plot.
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We finally tested whether an enzymatic digest to remove contaminating human
DNA could further improve P. vivax genome coverage. Modification-dependent restric-
tion endonucleases (MDREs), such as MspJI and FspEI, which specifically recognize
cytosine C-5 methylation or hydroxymethylation (28), have been used to selectively
degrade human DNA in P. falciparum clinical samples. Enzyme digest of DNA extracted
from clinical samples with 80% human contamination has previously been shown to
enrich P. falciparum DNA ~ninefold for more efficient WGS (29). However, when we
performed a digest with MspJI and FspEI enzymes on gDNA extracted from whole
blood obtained from patients with P. vivax infection, we observed either no change or
markedly decreased genome coverage in the 5 enzyme-digested samples (see Fig. S4
in the supplemental material).
SWGA and WGS of P. vivax from patient samples. To test the utility of SWGA for
variant calling and population genetics analysis of P. vivax from unprocessed clinical
blood samples, we used primer set pvset1920 to perform SWGA on P. vivax gDNA from
18 whole-blood and 4 dried blood spot samples collected from symptomatic patients
with P. vivax infection in Peru. Since the whole-blood samples had not been leukocyte
filtered, they had significant contamination with human DNA, with less than 1.5% of
reads mapping to the Sal-1 reference genome in unamplified samples (not shown). For
all samples, SWGA significantly increased the proportion of reads that mapped to the
P. vivax Sal-1 reference genome, resulting in higher genome coverage and higher
percentages of callable total- and core-genome regions (covered by 5 reads) (Ta-
ble 1). Comparison of the SWGA-amplified samples to 10 leukocyte-filtered samples
from a field study in Peru which were sequenced to a similar depth (1.5 0.2 billion bp
sequenced for SWGA samples versus 1.5 0.5 billion bp for leukocyte-filtered samples)
showed that SWGA yields a twofold increase in the percentage of sequencing reads
that map to the P. vivax genome and an average 5 P. vivax core-genome coverage of
60.1% 26.0%, compared to 43.7% 41.4% for leukocyte-filtered samples (10). For the
4 dried blood spot samples, we achieved an average 5 core-genome coverage of
54.0%  34.6%.
FIG 3 Testing of SWGA primer sets on DNA from an unprocessed, P. vivax-infected blood sample. (A) Unamplified DNA
(black) and DNA amplified with SWGA primer set pvset1 (blue) or pvset1920 (red) was sequenced on a MiSeq (Illumina).
The percentages of MiSeq reads that mapped to the P. vivax Sal-1 reference genome in Geneious (version 9.1) (39) were
plotted for both unamplified and SWGA-amplified samples. (B) The 1 P. vivax genome coverage is shown relative to the
total sequencing depth (in millions of base pairs sequenced) for samples subjected to SWGA with pvset1920 or pvset1 and
for unamplified DNA.
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There was a trend toward improved mean coverage and percentage of the genome
callable in samples with higher parasite densities (see Fig. S5 in the supplemental
material). This is consistent with previous SWGA results for P. falciparum (22) and results
from other P. vivax-enriching methods, such as hybrid selection (16). Samples subjected
to SWGA yielded similar 5 genome coverage per sequenced base pair compared to
that obtained by direct sequencing of a leukocyte-filtered patient sample (Fig. 4A). The
percentage of the 14 large chromosomes of P. vivax considered callable for samples
that underwent SWGA fell within the range of that obtained by direct sequencing of
leukocyte-filtered samples (Fig. 4B). Additionally, post-SWGA sequences yielded similar
levels of mean base quality when normalized across 100-bp windows of various %GC
TABLE 1 Sequencing statistics for P. vivax sequences from clinical samples that underwent selective whole-genome amplificationa
Enrichment technique
(sample)
No. of parasites/l
(% parasitemia)b
Total no. of
bp sequenced
(billions)
Reads aligned
to P. vivax
reference (%)
Mean coverage
()
% callablec:
Genome Core genome
SWGA (18 whole-blood samples)
1 45,680 (0.9) 1.42 89.5 37.1 71.7 83.6
2 34,268 (0.7) 1.68 80.9 37.9 72.9 85.1
3 28,474 (0.6) 1.41 88.3 30.4 66.6 76.3
4 25,680 (0.5) 1.50 65.1 13.8 40.2 42.1
5 19,241 (0.4) 2.00 71.9 44.1 79.9 95.4
6 13,064 (0.3) 1.84 83.7 43.8 76.1 90.4
7 11,438 (0.2) 1.52 79.5 20.3 32.7 34.5
8 9,961 (0.2) 1.36 75.4 31.0 74.6 87.3
9 8,842 (0.2) 1.84 74.2 29.6 72.9 84.7
10 7,382 (0.1) 1.23 72.6 23.7 65.6 73.6
11 6,258 (0.1) 1.41 82.8 25.1 59.5 67.7
12 5,135 (0.1) 1.82 54.9 18.0 34.8 37.0
13 2,942 (0.06) 1.16 40.7 12.9 52.1 57.9
14 1,873 (0.04) 1.44 17.0 5.7 13.7 14.1
15 1,652 (0.03) 1.52 53.2 23.5 52.0 57.3
16 1,471 (0.03) 1.26 44.0 12.9 21.5 22.9
17 537 (0.01) 1.92 22.5 11.1 38.1 40.7
18 495 (0.01) 1.44 28.6 10.0 30.0 30.5
Avg  SD 12,466  13,107.2 1.5  0.2 62.7  23.2 23.9  11.8 53.1  20.9 60.1  26.0
SWGA (4 dried blood
spot samples)
DBS-4 50,330 (1.0) 1.97 79.4 34.8 74.4 87.4
DBS-3 35,730 (0.7) 1.91 46.8 20.9 69.5 80.3
DBS-2 5,932 (0.1) 0.93 11.0 3.0 25.8 24.2
DBS-1 3,885 (0.08) 1.57 17.7 4.2 23.2 24.1
Avg  SD 23,962  22,826.4 1.6  0.5 38.7  27.1 15.7  13.1 48.2  27.5 54.0  34.6
Leukocyte filtration
(10 whole-blood samples)
Mdio01 NA 2.43 25.7 6.35 8.2 5.5
Mdio02 NA 0.80 16.2 1.65 1.3 0.6
Mdio03 NA 2.04 19.9 8.23 57.2 61.2
Mdio04 NA 1.52 14.2 1.97 18.7 9.6
Mdio05 NA 1.56 49 22.3 78.1 91.7
Mdio06 NA 1.62 55.4 28.1 79.6 93.4
Mdio07 NA 1.46 20.7 4.23 15.8 11.3
Mdio08 NA 1.50 30.3 10.6 67.3 74.9
Mdio09 NA 0.74 18.3 1.74 1.6 0.8
Mdio10 NA 1.26 43.5 16.1 76 88.1
Avg  SD NA 1.5  0.5 31.4  14.8 10.1  9.2 40.4  34.0 43.7  41.4
aSequencing statistics were determined using the Genome Analysis Toolkit’s (GATK) DepthofCoverage tool. The core genome was defined by coordinates determined
in the large-scale P. vivax sequencing study by Pearson et al. (15). The leukocyte-filtered sequencing statistics presented here are from P. vivax clinical samples
obtained from a previously published study in Peru (10).
bNA, not applicable.
cCovered by 5 reads.
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contents in the reference genome compared to the results for leukocyte-filtered
samples (Fig. 5).
Variant analysis. To examine the utility of post-SWGA sequences for variant
analysis, we called 45,821 single-nucleotide polymorphisms (SNPs) from the whole-
blood and dried blood spot samples that were subjected to SWGA. For the whole-blood
samples, an average of 14,463 SNPs was identified per sample, which is consistent with
prior studies of P. vivax field isolates (10). Compared to the results for leukocyte-filtered
samples, SNP characteristics such as SNP rate, transition-to-transversion (Ti/Tv) ratio,
and nonsynonymous-to-synonymous ratio were nearly identical in the samples that
underwent SWGA (Table 2).
In addition, the proportions of SNPs that were exonic, intronic, intergenic, or at 5=
and 3= untranslated regions were similar between samples prepared using the two
methods of P. vivax enrichment. We also detected SNPs in several known drug
resistance genes previously detected in samples from Peru (10) and Colombia (8) in the
whole-blood and dried blood spot samples (Table 3; see also Table S1 in the supple-
mental material), further validating the utility of sequences derived from SWGA for
variant calling. This includes several intronic mutations around a putative chloroquine
resistance transporter gene (pvcrt), in addition to coding mutations in the dihydrofolate
reductase (pvdhfr), multidrug resistance protein 1 (pvmdr1), multidrug resistance pro-
tein 2 (pvmrp2), and dihydropteroate synthetase (dhps) genes.
We also compared sample clonality estimates of post-SWGA sequences to micro-
satellite analyses on the same unamplified samples. We estimated the clonality of the
6 post-SWGA sequences with the highest coverage using the Fws statistic, a measure of
within-host diversity previously used to characterize multiplicity of infection in Plas-
modium falciparum patient samples (Table 4) (5, 30). An Fws score of0.95 indicates low
within-host diversity and infection with a single parasite, while an Fws score of 0.70 is
suggestive of a multiclonal infection. Microsatellite analysis on these same 6 unamplified
samples indicated that all were clonal, except for sample 9, where the presence of 2
microsatellite markers at more than one position suggested that it could be a multiclonal
sample. However, for all 6 post-SWGA sequences, the Fws score was0.95, suggesting that
FIG 4 Comparison of P. vivax genome coverage generated from samples treated with SWGA and with leukocyte filtration. (A) P. vivax genome
coverage (5) is shown relative to total sequencing depth (in millions of base pairs sequenced) for a sample amplified with pvset1920 (sample
5) and for a leukocyte-filtered sample (Mdio6). Both samples were sequenced on an Illumina HiSeq. (B) The percentages of the 14 chromosomes
that were callable (covered by 5 reads) for samples that underwent SWGA (colored lines) or leukocyte filtration (black dashed lines) were
compared between multiple samples.
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all were clonal infections. Thus, while SWGA does not introduce errors that lead to a falsely
low Fws, it may lead to underestimations of clonality in multiclonal samples.
Finally, we constructed a neighbor-joining tree using core-genome SNPs to deter-
mine the relatedness of our samples to one another and to other P. vivax isolates from
FIG 5 GC bias plots for P. vivax genomes generated following leukocyte filtration (A) or SWGA (B). GC
bias plots were generated using Picard (version 2.0.1) on aligned sequencing reads from two different
clinical samples that underwent leukocyte filtration (A) or selective whole-genome amplification (B). The
number of windows with a given GC content are plotted with red bars; the base quality (green line) and
normalized coverage (open blue circles) are plotted for different levels of GC content for both methods
of P. vivax gDNA enrichment.
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Peru and around the world (Fig. 6). In this tree, our samples, which were from the
Iquitos region of Peru, clustered with one another and were most closely related to
leukocyte-filtered samples from another region of Peru (10). They also exhibited the
expected degree of relatedness to previously published P. vivax sequences derived
from other leukocyte-filtered (15), hybrid-selected (17), and monkey-adapted (19)
clinical samples from diverse areas of the world, further validating the use of post-
SWGA sequences from downstream analyses.
DISCUSSION
In this study, we validate SWGA as a cost-effective, robust method to enrich P. vivax
gDNA from unprocessed whole-blood and dried blood spot clinical samples to improve
the efficiency and decrease the cost of subsequent WGS. This is a method that can
be applied to clinical samples infected with other malaria species, such as P. malariae,
P. ovale curtisi, and P. ovale wallikeri, where parasite densities are low, and where
there is no routine ex vivo culture (31), though species-specific primer sets would likely
be required. SWGA utilizes readily available reagents, does not require processing at the
time of sample collection, and can be performed in a simple, overnight reaction. While
several methods have been used successfully to enrich P. vivax gDNA for WGS from
infected whole-blood samples, most are resource and labor intensive. Short-term ex
vivo culture of P. vivax isolates or adaptation to growth in monkeys produces a large
amount of P. vivax DNA, but these methods require significant resources. Single-cell
sequencing allows for highly sensitive dissection of multiclonal samples; however, this
approach requires cryopreserved samples and specialized laboratory equipment (20).
While leukocyte filtration is cost-effective and efficient, it is not always possible to
perform at field sites with limited infrastructure, because samples require refrigeration
TABLE 3 Nonsynonymous SNPs in known drug resistance genes detected in Plasmodium vivax samples that underwent selective whole-
genome amplification (SWGA)
Locus Chromosome Position
Reference
allelea
Alternate
alleleb
Amino acid
changec
No. of samples bearing indicated allele
(no. confidently genotyped)
pvcrt-0 (PVX_087980) 1 331151 T C Intron 17 (18)
331819 G A Intron 11 (18)
332453 T C Intron 18 (18)
332874 A C Intron 18 (18)
pvdhfr (PVX_089950) 5 964763 C G, A Ser58Arg 12 (12)
964939 G A Ser117Asn 16 (16)
pvmdr1 (PVX_080100) 10 363223 A G Thr958Met 12 (12)
363374 T G Met908Leu 11 (11)
365435 C A Val221Leu 1 (12)
pvmrp2 (PVX_124085) 14 2043859 G C Gln1407Glu 11 (13)
2045050 C T Val1010Met 14 (15)
2047090 G A Pro330Ser 1 (15)
2047233 C A Arg282Met 13 (14)
2047816 C G Glu88Gln 3 (18)
dhps (PVX_123230) 14 1257856 G C Ala383Gly 9 (15)
1258389 C T Met205Ile 10 (12)
aAllele of the P. vivax Sal-1 reference genome at the indicated position.
bAllele found in P. vivax samples from Peru that underwent SWGA.
cAmino acid change resulting from base change from the reference to the alternate allele.
TABLE 2 Comparison of single-nucleotide polymorphism characteristics of Plasmodium vivax sequences after selective whole-genome
amplification (SWGA) and leukocyte filtrationa
Sample preparation
method
SNP characteristic
Nonsynonymous-to-synonymous
ratio (SNP effect)
Transition/transversion
ratio
No. (%):
SNPs
per baseExonic Intronic Intergenic
SWGA 1.41 20,865 (40) 3,714 (7) 25,178 (49) 0.002 1.63
Leukocyte filtration 1.36 18,365 (40) 3,029 (7) 23,157 (50) 0.002 1.74
aSamples for SWGA were obtained from Iquitos, Peru, and samples for leukocyte filtration were from a previously published study done in Madre de Dios, Peru (10).
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within 6 hours to minimize white blood cell lysis and reduce irreversible contamination
from human DNA. Hybrid selection is less labor intensive, but the production of the
RNA baits used for capture requires either large amounts of P. vivax Sal-1 DNA or costly
commercially synthesized RNA bait.
Using SWGA, we achieved a higher-than-average callable P. vivax genome than was
obtained for leukocyte-depleted clinical samples sequenced at a similar depth. SWGA
generally yielded the highest genome coverage for clinical samples with the highest
parasite densities, consistent with our experience with P. falciparum (22). For the 12
samples with parasite densities of5,000 parasites/l (0.1% parasitemia), we were able
to call, on average, 71.5% of the core genome, compared to 37% for the 6 samples with
parasite densities of 5,000 parasites/l. Increased sequencing effort is needed to
obtain maximal genome coverage for samples with lower parasite densities (see
Table S2 and Fig. S6 in the supplemental material). In these cases, the low genome
coverage is likely the result of stochastic amplification of a small number of starting
P. vivax genomes, which leads to very deep coverage of some genomic regions and little
or no coverage of others (22). If maximal genome coverage is desired, sequential SWGA
reactions with pvset1920 followed by pvset1 increase coverage slightly (3 to 5% 1
genome coverage) (see Fig. S7). Additionally, performing multiple independent SWGA
reactions on a sample and combining the sequencing reads can improve genome coverage
(4 to 12% 1 genome coverage) (see Fig. S8). Since multiple rounds of SWGA or pooling
the products from multiple reactions increases the workload and expenses for a small
improvement in genome coverage, we opted for a single amplification reaction with
pvset1920 for our samples. However, these protocol modifications may be useful if high
genome coverage is needed from samples with low parasitemia.
One potential limitation of SWGA of P. vivax from clinical samples is the ability to
amplify all clones in a multiclonal sample. One of our samples appeared to be
multiclonal by microsatellite analysis of the unamplified gDNA, and yet, Fws analysis of
the post-SWGA sequence suggested that the sample was comprised of a single clone.
It is possible that in this case, a majority clone was amplified preferentially over minority
clones. Another possibility is that the microsatellite marker assessment may overesti-
mate clonality. Analyses of additional multiclonal samples will be necessary to address
this question. Another important limitation of SWGA is that copy number variant (CNV)
detection is not possible on post-SWGA sequences. The uneven distribution of primer-
targeted motifs in the target genome results in peaks and troughs in mean genome
coverage that can confound CNV detection methods. Finally, SWGA requires long
strands of gDNA for efficient amplification of the target genome and is unlikely to work
well on degraded or ancient DNA samples.
Whole-genome analysis has the potential to reveal much about the biology and
epidemiology of P. vivax infections. For example, comparison of recurrent infections
using WGS can help distinguish relapse due to reactivation of hypnozoites from
reinfection or drug resistance, an epidemiological distinction of public health impor-
tance. SWGA enables high-quality and cost-effective WGS of P. vivax from unprocessed
blood samples that would otherwise be impossible or prohibitively expensive to
sequence. Advanced technologies like SWGA will greatly facilitate future P. vivax
TABLE 4 Clonality estimates of samples that underwent selective whole-genome
amplification compared to microsatellite analysis from the unamplified samples
Sample Fws
No. of
heterozygous
SNPs
No. of microsatellite markers before SWGA in
microsatellite locus:
v23 v24 v25 v28 v30 v33
1 0.98 377 266 170 102 85 149 153
2 0.97 446 266 170 102 85 149 163
5 0.97 372 266 171 102 86 150 153
6 0.98 326 266 170 102 86 149 153
8 0.98 300 282 167 102 94 136 134
9 0.97 354 282 163 99,94 86,118 143,150 151
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whole-genome sequencing projects, thereby improving our ability to understand and
combat the most widespread form of malaria.
MATERIALS AND METHODS
Patient sample collection and preparation. The P. vivax-infected DNA sample used for initial
testing of selective amplification primer sets (MRL2) was provided by the Malaria Reference Laboratory
of the London School of Hygiene and Tropical Medicine, London, United Kingdom. The six dried blood
spot samples used in this study were collected from patients with symptomatic P. vivax infection in Peru.
FIG 6 Neighbor-joining tree of Plasmodium vivax clinical samples from different regions of the world. The tree was constructed with core-genome-wide SNP
data from P. vivax samples that underwent selective whole-genome amplification (Peru-SWGA-1 through Peru-SWGA-18) and P. vivax clinical samples from
previously published studies that underwent leukocyte filtration (15) (Thailand-PD0169, Thailand-PD0168, Thailand-PD0166, Thailand-PD-0167, PNG-0050,
PNG-0065, PNG-0068, Vietnam-PV0025, Vietnam-PV0053, Vietnam-PV0056, and Vietnam-PV0061), hybrid selection (17) (Colombia-30102100437, Colombia-490,
Colombia-438A, Colombia-30101099036, Thailand-VKTS-36, Thailand-VKBT-73, Thailand-VKBT-58, Thailand VKBT-71, Thailand-VKBT-100, PNG-73, PNG-58,
PNG-012, PNG-014, and PNG-025), or adaption to growth in splenectomized monkeys (19) (BrazilI and IndiaVII) prior to sequencing. Bootstrap values are shown
on each corresponding branch.
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Parasitemia was quantified with real-time PCR, and gDNA was extracted using a QIAamp DNA blood
minikit (Qiagen).
Eighteen whole-blood samples used for additional testing and further sequencing analysis were
derived from whole-blood samples collected from patients with symptomatic P. vivax infections from two
sites around Iquitos, Peru, during a study conducted by U.S. Naval Medical Research Unit No. 6 (32). Thick
blood smears were examined to identify the parasite species and to determine the level of parasitemia.
Parasite density was calculated by counting the number of asexual parasites per 200 white blood cells
in the thick smear (Assuming an average of 6,000 white blood cells per l). Each blood smear was
examined by two microscopists independently and by a third microscopist in the event of a discrepancy.
The final parasite density was calculated as the average of the density readings from the two concordant
microscopists. Whole-blood samples were collected in the field using EDTA-containing Vacutainer tubes.
Samples were frozen and transported to the central laboratory until further processing. DNA was isolated
from thawed whole blood using a QIAamp DNA blood minikit (Qiagen) following the manufacturer’s
recommendations and as described elsewhere (33). Samples were subsequently resuspended in Tris-
EDTA (TE) buffer, and gDNA was quantified using a Qubit 2.0 fluorometer.
Primer design. The initial set of pvset1 primers was designed as described previously (22). Primer set
pvset1920 was designed using the swga program, which scores primer sets based on their selectivity and
evenness of binding (measured using the Gini index) and, thus, automates and improves primer
selection. The source code of swga, along with download links and documentation, are available at
https://www.github.com/eclarke/swga. pvset1920 was designed to specifically amplify longer regions
(195,000 bp) of the P. vivax reference genome (Sal-1) that were GC rich (48.5 to 50.6%) and yielded low
genome coverage following SWGA with pvset1. A total of 1,939 primer sets were identified that exhibited
a minimum background binding distance of 25,000 bp and a maximum foreground binding distance of
37,000 bp. These were scored using swga’s composite primer scoring algorithm (Gini score foreground
mean/background mean), and the set with the lowest score (pvset1920) was chosen for testing.
pvset1 consists of the following 10 primers, with asterisks indicating phosphorothioate bonds
that are necessary to prevent degradation by phi29: 5=-CGTTG*C*G-3=, 5=-TTTTTTC*G*C-3=, 5=-TCGT
G*C*G-3=, 5=-CGTTTTTT*T*T-3=, 5=-TTTTTTTC*G*T-3=, 5=-CCGTT*C*G-3=, 5=-CGTTTC*G*T-3=, 5=-CGTTTC
*G*C-3=, 5=-CGTTTT*C*G-3=, and 5=-TCGTTC*G*T-3=. pvset1920 consists of the following 12 primers:
5=-AACGAAGC*G*A-3=, 5=-ACGAAGCG*A*A-3=, 5=-ACGACGA*A*G-3=, 5=-ACGCGCA*A*C-3=, 5=-CAACG
CG*G*T-3=, 5=-GACGAAA*C*G-3=, 5=-GCGAAAAA*G*G-3=, 5=-GCGAAGC*G*A-3=, 5=-GCGGAAC*G*A-3=,
5=-GCGTCGA*A*G-3=, 5=-GGTTAGCG*G*C-3=, and 5=-AACGAAT*C*G-3=.
Selective whole-genome amplification. Thirty to 70 ng of input DNA was added to a 50-l reaction
mixture containing 3.5 M SWGA primers, 30 U phi29 DNA polymerase enzyme (New England Biolabs),
1 phi29 buffer (New England Biolabs), 4 mM dNTPs (Roche), 1% bovine serum albumin, and water. The
reaction was carried out on a thermocycler with cycling conditions consisting of a ramp down from 35°C
to 30°C (10 min per degree), 16 h at 30°C, 10 min at 65°C, and hold at 4°C. The samples were diluted 1:1
with DNase-free, RNase-free water and purified with AMPure XP beads (Beckman-Coulter) at a 1:1 ratio
according to the manufacturer’s protocol. When a second round of selective amplification was per-
formed, the reaction mixture contained 100 to 200 ng of the AMPure XP-purified product from the first
reaction.
Methylation digest. One hundred twenty-five to 500 ng of gDNA extracted from P. vivax-infected
whole-blood samples was digested with 5 units of FspEI (New England Biolabs) and 5 units of MspJI (New
England Biolabs) enzymes in a 30-l reaction mixture. A mock digest with an identical amount of gDNA
and no enzymes was run in parallel. Samples were digested for 2 h at 37°C and then heat inactivated at
80°C for 15 min. For coverage analysis, rarefaction analysis was performed on Illumina MiSeq sequencing
reads derived from samples digested with MspJI or FspEI (digest and SWGA) or mock digested with no
enzyme prior to SWGA with primer set pvset1920. The coverage obtained by mapping 200,000 MiSeq
sequencing reads (~25 million bp of sequencing depth) was compared between digested and mock-
digested samples. P values were obtained using the two-tailed t test.
Whole-genome sequencing. The SWGA products and unamplified DNA used for primer set testing
were sequenced on an Illumina MiSeq using a modified Nextera library preparation method. For HiSeq runs,
next-generation-sequencing libraries of SWGA products were prepared using the Nextera XT DNA preparation
kit (Illumina) according to the manufacturer’s protocol. These samples were pooled and clustered on a HiSeq
2500 (Illumina) in Rapid Run mode with 100-bp paired-end reads. For the coverage analysis of leukocyte-
filtered samples, fastq files from a prior study of P. vivax field samples (10) were used.
Raw fastq files were aligned to the Sal-1 reference genome (PlasmoDB version 13, http://plasmodb.org/
common/downloads/release-13.0/PvivaxSal1/fasta/data/) using the Burroughs-Wheeler Aligner (version
0.7.8) (34) and SAMtools (version 0.1.19) (35, 36) in the Platypus pipeline, as previously described (37).
Picard (version 2.0.1) was used to remove unmapped reads, and the Genome Analysis Toolkit (GATK) (38)
was used to realign the sequences around the indels. Picard’s CollectGcBiasMetrics tool was used to
generate the GC bias plots. GATK’s DepthOfCoverage tool was used to determine the percentages of the
total and core genomes covered by 5 reads, mean coverage, and coverage over the core genome. The
coordinates of the P. vivax core genome, which excludes subtelomeric and hypervariable regions with
significantly higher read mapping errors, was obtained from a recent analysis of hundreds of P. vivax
sequences from clinical isolates (15).
For rarefaction analyses, sequences were aligned with smalt (Wellcome Trust Sanger Institute) and
mapped with custom scripts in R (https://www.r-project.org/). To visualize base composition across chro-
mosomes, plots were created in Geneious (version 9.1) (39) using the Sal-1 P. vivax reference sequences
and 25-bp windows. Plots of chromosome coverage were created with IGVTools (version 2.3.40) (40, 41).
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Variant calling and analysis.We followed the GATK’s best practices to call variants (42, 43). The aligned
sequences were run through GATK’s HaplotypeCaller in “reference confidence” mode to create genomic
variant call format (GVCF) files for each sample. This reference confidence model highlights areas of the
genome that are likely to have variation and produces a comprehensive record of genotype likelihoods and
annotations for each site. The samples were joint genotyped using the GenotypeGVCFs tool.
Variants were further filtered based on quality scores and sequencing bias statistics based on default
parameters from GATK. SNPs were filtered out if they met any of the following criteria: quality depth (QD)
of 2.0, mapping quality (MQ) of 50.0, Phred-scaled P value using Fisher’s exact test to detect strand
bias (FS) of60.0, symmetric odds ratio (SOR) of4.0, Z score from Wilcoxon rank-sum test of alternative
versus reference read-mapping qualities (MQRankSum) of 12.5, and ReadPosRankSum (RPRS)
of 8.0. Variants were annotated using snpeff (version 4.2) (44).
Fws of samples with the highest genome coverage was estimated using moimix (https://doi.org/
10.5281/zenodo.58257), a package available through R. The package calculates the Fws statistic using the
equation Fws  1  (Hw/Hs), where Hw is the within-host heterozygosity and Hs is the population-level
heterozygosity (5, 30). The core P. vivax genome, as defined by Pearson et al. (15), was used for
core-genome analysis. For microsatellite genotyping, five neutral microsatellite loci of significant vari-
ability in the Peruvian Amazon were typed in a previous study (32). If there was more than one marker
at any given locus, the sample was considered multiclonal, per prior genotyping studies (45–47).
A neighbor-joining tree was constructed using SNPs from the core P. vivax genome from sequences
obtained in this study, along with sequences from previously published studies that are available in the
NCBI Short Read Archive. The Mdio samples were from a previous study conducted by our laboratory in
Peru (10), and the rest of the sequences were obtained from two recent large-scale P. vivax sequencing
studies (15, 17). In order to assess the phylogenetic relationships of sequenced isolates, we constructed
a multiple sequence alignment from filtered SNPs called in GATK using an in-house Perl script. This
alignment was used as the input for maximum-likelihood phylogenetic analysis in the randomized
accelerated maximum-likelihood program (RAxML) (48) with 500 pseudoreplicates using the generalized
time-reversible model, and the resulting tree was visualized in Dendroscope (49).
Ethics approval and consent to participate. The sample from Malaria Research Laboratories (MRL)
was an anonymized DNA sample previously collected by the MRL and provided under the MRL’s remit
to undertake epidemiological surveillance relevant to imported malaria in the United Kingdom. The
protocol for the collection of field samples was approved by the Institutional Review Board of the U.S.
Naval Medical Research Center (Protocol NMRCD.2005.0005) and the National Institutes of Health of Peru
(protocol 009-2004) in compliance with all applicable federal regulations governing the protection of
human subjects. All adult subjects provided written informed consent, and all children 8 to 17 years old
provided verbal assent to participate in the study.
Accession number(s). The P. vivax genome Illumina sequencing reads of the 22 samples used for
variant analysis in this study are available in the National Center for Biotechnology Information’s
Sequence Read Archive with the study accession number SRP095853.
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